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Adoptive transfer of Tumor Infiltrating Lymphocytes
(TIL), T-cell receptor (TCR)-transduced PBL and Chi-
meric Antigen Receptor (CAR)-transduced PBL have
proven to be clinically effective. CARs have evolved by
introducing cytoplastic costimulatory domains. Higher
cytokine secretion and longer persistence of CAR-
transduced T-cells in vivo imply important roles of cost-
imulatory signals. In contrast, costimulation of TIL or
TCR-transduced PBL in vivo relies on the expression of
costimulatory receptors on T-cells and ligands on tumor
cells or antigen presenting cells (APCs). One way to give
T-cells their desired costimulation signal independent of
the endogenous receptor/ligand expression would be to
introduce a fusion molecule that is comprised of a recep-
tor whose ligand is frequently expressed on tumor cells
and an intra-cellular costimulatory domain. In a pursuit
for a “universal costimulator” that is applicable to various
tumors, we produced fusions of CD2 and various costi-
mulators such as CD28, 4-1BB, ICOS, CD27 and OX-40
(Figure 1). CD2 is the receptor for CD58 that is expressed
on various tumor cells. Since CD2-CD58 complex loca-
lizes to the Supramolecular Activation Complex (SMAC)
on activation of TCR, CD2-costimulators may signal in
a TCR-activation dependent manner. Human PBL were
retrovirally transduced with genes that encode NY-ESO-
1-reactive TCR and each CD2-costimulator. In vitro
co-culture assay showed higher IFN-g and IL-2 secretion
by CD2-CD28 and higher IFN-g by CD2-OX40. To exam-
ine the in vivo effect of these fusion costimulators, vascu-
larized SK23 melanoma tumor was established in NOD
scid gamma (NSG) immunodeficient mice and human
CD8+ T-cells transduced with anti-NY-ESO1 TCR and
each fusion costimulator were injected. Out of five
costimulators tested, CD2-CD28 showed a significant
enhancement of anti-tumor effect. These results suggest
that the CD2-CD28 costimulator may improve TIL and
TCR-transduced PBL therapy.
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